It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Parkinson’s disease (PD) and Multiple System Atrophy (MSA) are progressive and unremitting neurological diseases that are neuropathologically characterized by α-synuclein inclusions. Increasing evidence supports the aggregation of α-synuclein in specific brain areas early in the disease course, followed by the spreading of α-synuclein pathology to multiple brain regions. However, little is known about how the structure of α-synuclein fibrils influence its ability to seed endogenous α-synuclein in recipient cells. Here, we aggregated α-synuclein by seeding with homogenates of PD- and MSA-confirmed brain tissue, determined the resulting α-synuclein fibril structures by cryo-electron microscopy, and characterized their seeding potential in mouse primary oligodendroglial cultures. The combined analysis shows that the two patient material-amplified α-synuclein fibrils share a similar protofilament fold but differ in their inter-protofilament interface and their ability to recruit endogenous α-synuclein. Our study indicates that the quaternary structure of α-synuclein fibrils modulates the seeding of α-synuclein pathology inside recipient cells. It thus provides an important advance in the quest to understand the connection between the structure of α-synuclein fibrils, cellular seeding/spreading, and ultimately the clinical manifestations of different synucleinopathies.
Quaternary structure of α-synuclein fibrils characterized from human patients with Parkinson’s disease and Multiple System Atrophy modulates seeding in mouse primary oligodendroglial cultures.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Forschungszentrum Jülich GmbH, Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Jülich, Germany (GRID:grid.8385.6) (ISNI:0000 0001 2297 375X)
2 German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426)
3 Max Planck Institute for Multidisciplinary Sciences, Department of Molecular Biology, Göttingen, Germany (GRID:grid.4372.2) (ISNI:0000 0001 2105 1091)
4 Biomedical Research Foundation of the Academy of Athens (BRFAA) 4, Center of Clinical, Experimental Surgery, & Translational Research, Athens, Greece (GRID:grid.417975.9) (ISNI:0000 0004 0620 8857)
5 Seoul National University, Department of Biomedical Sciences, Neuroscience Research Institute, College of Medicine, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); University of California Berkeley, Nutritional Sciences and Toxicology Department, Berkeley, USA (GRID:grid.47840.3f) (ISNI:0000 0001 2181 7878)
6 The University of Sydney, Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); University of New South Wales & Neuroscience Research Australia, School of Medical Sciences, Randwick, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
7 Seoul National University, Department of Biomedical Sciences, Neuroscience Research Institute, College of Medicine, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
8 German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426); Max Planck Institute for Multidisciplinary Sciences, Department for NMR-based Structural Biology, Göttingen, Germany (GRID:grid.4372.2) (ISNI:0000 0001 2105 1091)
9 Forschungszentrum Jülich GmbH, Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Jülich, Germany (GRID:grid.8385.6) (ISNI:0000 0001 2297 375X); Heinrich Heine University Düsseldorf, Physics Department, Düsseldorf, Germany (GRID:grid.411327.2) (ISNI:0000 0001 2176 9917)